Cardiac Sarcoidosis Multi-Center Prospective Cohort (NCT01477359)
Cardiac Sarcoidosis Multi-Center Prospective Cohort Study
🩺 Plain-English Summary (8th-Grade Level)
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity. There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS. A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
Who can join: Review the eligibility criteria below.
Location: Libin Cardiovascular Institute of Alberta — Calgary, Alberta
Age range: 18 Years to 99 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Libin Cardiovascular Institute of Alberta — Calgary, Alberta
- University of Alberta Hospital — Edmonton, Alberta
- St. Paul's Hospital — Vancouver, British Columbia
- QEII Health Sciences Center — Halifax, Nova Scotia
- Hamilton Health Sciences Centre — Hamilton, Ontario
- London Health Sciences Centre — London, Ontario
- Southlake Regional Health Centre — Newmarket, Ontario
- University of Ottawa Heart Institute — Ottawa, Ontario
- Toronto General Hospital — Toronto, Ontario
- Montreal Heart Institute — Montreal, Quebec
- Centre Hospitalier de l"Universite de Montreal-Hotel Dieu — Montreal, Quebec
- McGill University Health Centre — Montreal, Quebec
- Prairie Vascular Research Inc-Regina General Hospital — Regina, Saskatchewan
- Hokkaido University — Sapporo,
📞 Contact the Study Coordinator
Phone: (613) 696-7000
Email: jryan@ottawaheart.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiac Sarcoidosis
- A Trial of Baricitinib in Patients With Cardiac Sarcoidosis — Palo Alto, California
- Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression — Philadelphia, Pennsylvania
- Repurposing Tilmanocept for Cardiac Sarcoidosis — Durham, North Carolina
- Cardiac Sarcoidosis Randomized Trial — New Haven, Connecticut
- Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) — Rochester, Minnesota
Explore by condition: All Cardiac Sarcoidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.